Clinical Trial

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-09
notable Trial sites reduced: 110 -> 107 locations 2026-04-09
Trial Details
NCT Number NCT06958211
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa
Enrollment 573 participants
Start Date 2025-06-12
Primary Completion 2026-10-09 (estimated)
Study Completion 2027-07-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-08